Why Your Wegovy Dose Increases Over Time

Step 1: Why treatment starts so low

Wegovy's first dose is 0.25 mg once a week. That might feel underwhelming when you are hoping to see movement on the scale, but it is deliberate. Semaglutide slows how quickly your stomach empties and changes the signals your gut sends to your brain about hunger. At full strength those effects are powerful; introduced too abruptly, they produce significant nausea, vomiting and fatigue in many people.

The 0.25 mg phase (typically four weeks) is about acclimatisation. Your digestive system is learning a new rhythm. Most people notice only mild side effects at this level, which is exactly the point. Pushing straight to a therapeutic dose to speed things up is the kind of shortcut that tends to end with people abandoning treatment altogether because they feel too unwell to continue. The Wegovy overview on our site explains the full mechanism if you want the background.

One practical note: if your first pen arrives just before a bank holiday or you start mid-week and your refill is due over a long weekend, plan ahead. A gap in supply at the titration stage is worth flagging to your clinical team before it happens, not after.

Step 2: The middle doses, where tolerability and effectiveness start to converge

After the first month, the standard schedule moves to 0.5 mg, then 1.0 mg, then 1.7 mg, each roughly four weeks apart. This is where most people begin to notice real appetite change. Hunger becomes less insistent, portion sizes fall naturally, and energy levels often stabilise once the early GI effects have settled.

Each upward step can briefly revive the nausea or loose stools that eased at the previous dose. That is normal and usually short-lived. Your prescriber will want to know how you are tolerating the current dose before the next increase is authorised, which is why the titration chart is a guide, not a guarantee. If you are still struggling at 1.0 mg, it is entirely reasonable to stay there for eight weeks rather than four. Slower titration does not mean treatment has failed.

Side effects worth watching at each step: nausea, constipation, reflux, fatigue. Serious symptoms (severe persistent stomach pain that radiates to the back) need urgent medical attention and should not be waited out. The MHRA highlighted this in their January 2026 Drug Safety Update on GLP-1 medicines.

Step 3: Reaching 2.4 mg, and what happens if you get there and plateau

The 2.4 mg weekly dose is the standard maintenance dose for Wegovy, and clinical trial data published in the New England Journal of Medicine (STEP 1) showed an average body-weight reduction of around 15% over 68 weeks at this dose alongside lifestyle changes. Most of that effect builds gradually across months, so arriving at 2.4 mg is not the finish line, it is where the main work begins.

If weight loss slows or stalls at 2.4 mg, there is now a further option: the MHRA approved a 7.2 mg maintenance dose in early 2026, and a dedicated single-dose 7.2 mg pen followed in April 2026. Trials at that higher dose reported average weight loss approaching 20.7% over 72 weeks. Whether a patient moves to 7.2 mg is a clinical decision, and your prescriber will want to review your progress, your tolerability history, and your BMI before recommending it, so it helps to understand how a Wegovy increase works and what the process involves before that conversation. You can read more about what the evidence says on dose increases and weight loss to put those numbers in context.

If the 2.4 mg dose has not produced meaningful progress after six months, NICE guidance suggests reviewing whether continuing treatment is appropriate, another reason this conversation belongs with a prescriber, not a forum. For a practical look at how private treatment is structured and what it costs, our Wegovy cost page covers what is included in a transparent private price.

Step 4: When a dose increase is delayed or paused

Titration does not always run on a neat four-week clock. Several things can slow or pause an increase: persistent nausea that has not settled, a stomach bug that disrupts tolerance, a planned surgical procedure (you should always tell your anaesthetist you are taking a GLP-1 medicine), or simply a patient's preference to stay where they feel comfortable. None of these are failures.

What matters is that each decision is reviewed. At nume, every repeat order goes through a clinical review by a GPhC-registered prescriber before dispatch, there is no automatic rollover to the next dose. If you have questions about timing a dose change around travel, holidays or an upcoming procedure, our clinical team is reachable seven days a week. The FAQs also cover common titration queries. For a full picture of the schedule and what to expect at each level, the guide to when to increase your Wegovy dose goes into detail on timing decisions.